Immunovant Sciences GmbH

Immunovant Sciences GmbH is a Swiss-registered biopharmaceutical company based in Basel, Switzerland, and is part of the Roivant Sciences group. It operates as a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The company is a trailblazer in anti-FcRn technology, developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its lead investigational product, imeroprubart (IMVT-1402), is a novel, fully human monoclonal antibody that targets FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. Immunovant believes this candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection with dosing that may be tailored based on disease stage and severity. The company's vision is normal lives for people with autoimmune diseases, and it applies a patient-focused approach to help advance treatments for these individuals. Immunovant, Inc., the U.S.-listed entity (NASDAQ: IMVT), is headquartered in Durham, North Carolina, while Immunovant Sciences GmbH is the Swiss entity. The company is led by CEO Eric Venker, MD, PharmD, who has served on the Board of Directors since 2020 and is also President of Roivant Sciences. Immunovant's pipeline includes imeroprubart (IMVT-1402) and other anti-FcRn programs. The company is publicly traded on NASDAQ under the ticker IMVT.

Immunovant Sciences GmbH is a Swiss-registered biopharmaceutical company based in Basel, Switzerland, and is part of the Roivant Sciences group. It operates as a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. The company is a trailblazer in anti-FcRn technology, developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its lead investigational product, imeroprubart (IMVT-1402), is a novel, fully human monoclonal antibody that targets FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. Immunovant believes this candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection with dosing that may be tailored based on disease stage and severity. The company's vision is normal lives for people with autoimmune diseases, and it applies a patient-focused approach to help advance treatments for these individuals. Immunovant, Inc., the U.S.-listed entity (NASDAQ: IMVT), is headquartered in Durham, North Carolina, while Immunovant Sciences GmbH is the Swiss entity. The company is led by CEO Eric Venker, MD, PharmD, who has served on the Board of Directors since 2020 and is also President of Roivant Sciences. Immunovant's pipeline includes imeroprubart (IMVT-1402) and other anti-FcRn programs. The company is publicly traded on NASDAQ under the ticker IMVT.

Clinical-stage immunology company and trailblazer in anti-FcRn technology, developing targeted therapies for autoimmune diseases.

• Imeroprubart (IMVT-1402)

  A novel, fully human, monoclonal antibody that targets FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. It is being developed as a subcutaneous injection with dosing that may be tailored based on disease stage and severity.

1. 1Immunovant, Inc. (IMVT) - Official Websiteimmunovant.com
2. 2About Us :: Immunovant, Inc. (IMVT)immunovant.com
3. 3Our Leadership :: Immunovant, Inc. (IMVT)immunovant.com
4. 4Company Information :: Immunovant, Inc. (IMVT)immunovant.com
5. 5Immunovant Sciences GmbH (Switzerland) - Wikidatawikidata.org